Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
3 Months : From Jan 2020 to Apr 2020
SAN DIEGO, Jan. 10, 2020 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) ("Portola " or the "Company") for violations of federal securities laws.
On January 9, 2020, Portola announced that the drug, Andexxa, brought in about $28 million in revenue in the fourth quarter of 2019. Oppenheimer's analyst covering the stock wrote Andexxa's fourth-quarter revenues "were well below our $39 million estimate and $41 million consensus". Following this news, on January 10, 2020, Portola stock was down over 43% in early morning trading.
If you lost money, realized or unrealized on your Portola investment, and are interested in learning more about the investigation, please contact lead analyst Jim Baker (firstname.lastname@example.org) by email or phone at 619-814-4471. If emailing, please include a phone number.
Additionally, you can [click here to join this action]. There is no cost or obligation to you.
About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.
Johnson Fistel, LLP
Jim Baker, 619-814-4471
[click here to join this action]
View original content:http://www.prnewswire.com/news-releases/ptla-alert-johnson-fistel-launches-investigation-into-portola-pharmaceuticals-investors-encouraged-to-contact-firm-300985020.html
SOURCE Johnson Fistel, LLP